Document Detail

Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
MedLine Citation:
PMID:  18069029     Owner:  NLM     Status:  MEDLINE    
It is now emerging that, in patients who are at high risk for cardiovascular complications and, in particular, those with diabetes, the occurrence of late restenosis and thrombosis after treatment of coronary artery disease with drug-eluting stents is higher than earlier reports have suggested. Therefore, the aim of this study was to assess the prevalence of in-stent restenosis in a cohort of consecutive patients with diabetes treated for coronary disease in 2005 with drug-eluting stents [either sirolimus (58%) or paclitaxel (42%)]. The duration of follow-up was 9.0+/-3.4 months [mean+/-1 standard deviation (S.D.)]. A total of 154 patients (type 2 diabetes: 91%) were included in the study (age: 66+/-10 years), and the total number of implanted stents was 184. Two subjects died from cardiac causes, while myocardial infarction and (un)stable angina were observed in 3 (2%) and 39 (25%) patients, respectively. In-stent restenosis, appraised by angiography, was observed in 17 individuals (11%) after a mean follow-up of five months. Mean HbA(1c) in patients with restenosis was 7.6+/-1.8%. There was no difference in the rate of restenosis with sirolimus-(n=8) compared with paclitaxel-(n=9) eluting stents. Male gender, oral therapy for diabetes and stent diameter were predictors of in-stent restenosis. In conclusion, even over a medium-term period, in-stent restenosis remains a potential risk for coronary diabetic patients treated with drug-eluting devices.
M Kitoga; A Pasquet; V Preumont; J Kefer; M-P Hermans; J-L Vanoverschelde; M Buysschaert
Related Documents :
16077999 - Diagnostic accuracy of multislice computed tomography coronary angiography is improved ...
1386489 - Results of directional atherectomy of primary atheromatous and restenosis lesions in co...
19808139 - Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for ...
14627059 - Long-term resource use and cost of percutaneous transluminal coronary angioplasty versu...
8738859 - Effect of treatment with magnesium and potassium on mortality and reinfarction rate of ...
17947929 - Non-randomized, prospective, multi-centre evaluation of the absolute .035 peripheral se...
8267439 - Improved distal circulatory support for repair of descending thoracic aortic aneurysms.
21339469 - Safety, efficacy, and utility of platelet-rich fibrin matrix in facial plastic surgery.
20525759 - In patients with severe active aortic valve endocarditis, is a stentless valve as good ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Diabetes & metabolism     Volume:  34     ISSN:  1262-3636     ISO Abbreviation:  Diabetes Metab.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-19     Completed Date:  2008-05-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607599     Medline TA:  Diabetes Metab     Country:  France    
Other Details:
Languages:  eng     Pagination:  62-7     Citation Subset:  IM    
Service d'endocrinologie et nutrition, université catholique de Louvain, cliniques universitaires Saint-Luc, 10, avenue Hippocrate, 1200 Bruxelles, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Coronary Restenosis / epidemiology*,  mortality
Coronary Stenosis / therapy*
Diabetes Mellitus, Type 1 / therapy
Diabetes Mellitus, Type 2 / therapy
Diabetic Angiopathies / therapy*
Drug-Eluting Stents*
Immunosuppressive Agents / therapeutic use
Middle Aged
Retrospective Studies
Sirolimus / therapeutic use*
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of simultaneous dual-site TENS stimulation on experimental pain.
Next Document:  Adiponectin: an update.